Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
VivosRDGL -3.38% PB Ratio is 9.56 as of Aug. 02, 2026. The stock has 4 warning signs investors should review. Among 788 Medical Devices & Instruments companies, Vivos ranks worse than 90.36% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-02), Vivos's share price is $0.05737. Vivos's Book Value per Share for the quarter that ended in Mar. 2026 was $0.01. Hence, Vivos's PB Ratio of today is 9.56.
The historical rank and industry rank for Vivos's PB Ratio or its related term are showing as below:
RDGL'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 9.56
Current: 9.56
During the past 13 years, Vivos's highest PB Ratio was 9.56. The lowest was 0.00. And the median was 0.00.
RDGL's PB Ratio is ranked worse than 90.36% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs RDGL: 9.56
During the past 12 months, Vivos's average Book Value Per Share Growth Rate was -14.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -7.20% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vivos was 89.90% per year. The lowest was -51.40% per year. And the median was 26.05% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vivos PB Ratio Related Terms
Vivos PB Ratio Historical Data
* Premium members only.
The historical data trend for Vivos's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vivos's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vivos's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vivos's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vivos (RDGL) has a PB Ratio of 9.56 as of Aug. 02, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivos and its competitors. According to the industry distribution chart, Vivos ranks #712 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 90.4%.
Is Vivos' PB Ratio too high?
Vivos' current PB Ratio is 9.56. The Medical Devices & Instruments industry median PB Ratio is 2.06. Vivos' value of 9.56 is 364.1% above this industry median. Based on the distribution chart, Vivos ranks #712 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does Vivos' PB Ratio compare to ARAY and FOFA?
According to the Medical Devices & Instruments industry distribution chart, Vivos ranks #712 out of 788 companies for PB Ratio. This places Vivos in the lower half of its industry. The industry median PB Ratio is 2.06. Vivos' value of 9.56 is 364.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.06, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivos's current PB Ratio of 9.56 is 364.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivos and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos's current PB Ratio is 9.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos stock overvalued right now?
Vivos (RDGL) has a current PB Ratio of 9.56. The current PB Ratio is 9.56 and 364.1% above the Medical Devices & Instruments industry median of 2.06. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vivos (RDGL), the current PB Ratio is 9.56 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDGL has been successfully added to your 
